Severe Type 2 Diabetes Induces Reversible Modifications of Endothelial Progenitor Cells Which are Ameliorated by Glycemic Control

Maria Rosaria De Pascale¹,*, Giuseppe Bruzzese²,*, Ettore Crimi³,*, Vincenzo Grimaldi¹, Antonio Liguori², Sergio Brongo⁴, Michelangelo Barbieri⁵, Antonietta Piacia⁶, Concetta Schiano⁶, Linda Sommese¹, Nicola Ferrara⁷, Giuseppe Paolisso⁸, Claudio Napoli¹,⁵,⁶

¹U.O.C. Division of Immunohematology, Transfusion Medicine and Transplant Immunology, Department of Internal Medicine and Specialistics, Azienda Ospedaliera Universitaria (AOU), Second University of Naples, ²Division of Cardiology, ASL NA1, Pellegrini Hospital, Naples, Italy, ³Department of Anesthesia and Critical Care Medicine, University of Florida, Shands Hospital, Florida, USA, ⁴Department of Medicine and Surgery, Plastic Surgery Unit, University of Salerno, Salerno, Italy, ⁵Department of Medical, Surgical, Neurological, Aging and Metabolic Sciences, Second University of Naples, ⁶IRCCS Foundation SDN, ⁷Geriatrics Medicine, Department of Translational Medical Science, Federico II University of Naples, Naples, Italy

Background: Circulating endothelial progenitor cells (EPCs) play a critical role in neovascularization and endothelial repair. There is a growing evidence that hyperglycemia related to Diabetes Mellitus (DM) decreases EPC number and function so promoting vascular complications.

Aim of the Study: This study investigated whether an intensive glycemic control regimen in Type 2 DM can increase the number of EPCs and restores their function.

Methods: Sixty-two patients with Type 2 DM were studied. Patients were tested at baseline and after 3 months of an intensive regimen of glycemic control. The Type 2 DM group was compared to control group of subjects without diabetes. Patients with Type 2 DM (mean age 58.2±5.4 years, 25.6% women, disease duration of 15.4±6.3 years) had a baseline HgA1c of 8.7±0.5% and lower EPC levels (CD34+/KDR+) in comparison to healthy controls (p<0.01).

Results: The intensive glycemic control regimen (HgA1c decreased to 6.2±0.3%) was coupled with a significant increase of EPC levels (mean of 18%, p<0.04 vs. baseline) and number of EPCs CFUs (p<0.05 vs. baseline).

Conclusion: This study confirms that number and bioactivity of EPCs are reduced in patients with Type 2 DM and, most importantly, that the intensive glycemic control in Type 2 DM promotes EPC improvement both in their number and in bioactivity.

Keywords: Type 2 diabetes, Endothelial progenitor cells, Vascular disease, Regenerative medicine
Introduction

EPCs are bone marrow-derived cells mobilized from the vascular niche to the peripheral circulation in response to tissue injury (1-5). Circulating EPCs home to damaged or ischemic microcirculatory beds where they actively participate in endothelial repair and neovascularization (6-8). Insulin resistance and hyperglycemia in patients with DM result in endothelial dysfunction by promoting the progression of atherosclerosis and cardio circulatory complications (9-12). It is well established that DM is associated to a reduced availability and downregulation of EPCs with an altered pattern of plasma growth factors and anti-oxidant gene expression (13-18). Interestingly, EPCs can be reduced in pre-diabetic states (impaired fasting glucose and impaired glucose tolerance) with further significant decrease at the time of clinical diagnosis of diabetes (19). The detrimental effects of DM on EPC number and function can impair vascular repair and regenerative activity and lead to vascular complications and worse clinical prognosis (20, 21). The definitive mechanisms responsible for the effects of hyperglycemia on EPCs needs to be elucidated. Decreased availability and down regulation of EPCs can occur as dysfunction in their mobilization, differentiation, migration and adhesion secondary to increased oxidative stress, reduced nitric oxide availability, altered secretion functions and derangement of intracellular signal pathways such mitogen-activated protein kinase (MAPK)/c-Jun N-terminal kinase (JNK) and phosphoinositide 3-kinase pathways (11, 22-26). When diabetic patients are compared to the group of control subjects, glycemic control exerts a positive influence on clinical incidence of ischemic events, cardiovascular accidents, and micro or macroangiopathies (18).

In this study, we analyzed the features of EPCs in severe Type 2 DM and the possible reversible effects of glycemic control. In particular, we evaluated whether a period of intensive glycemic control (three months) can influence the number and dynamics of mobilization of EPCs.

Materials and Methods

Type 2 DM patients and healthy controls between 50 and 85 years of age were eligible for inclusion in the study and enrolled from outpatient clinic basis. The overall risk factor load of an individual patient using a risk factor score including age above 40 years, male gender, hypertension, smoking, family history for cardiovascular heart diseases, and hypercholesterolemia, were calculated. Patients with type 2 DM (mean age 58.2±5.4 years, 25.6% women, disease duration of 15.4±6.3 years) had a baseline HgA1c of 8.7±0.5%. Exclusion criteria were the presence of acutely decompensate heart failure; a history of leucopenia, thrombocytopenia, or severe hepatic and renal dysfunction, evidence for inflammatory or malignant disease; or unwillingness to participate. Glicemic control was achieved in Type 2 diabetic group with a balanced dietary regimen, as previously described in detail (27). Diabetic patients were subjected to dietary evaluation (by food questionnaire) during the screening visit and monthly during the severe glucose control. Diabetic subjects were encouraged to control the body weight during the study and dietary regimen was provided. The proposed diet had a composition that was on average 27−28% fat (>80% in the form of monoisaturated fatty acids), 12−14% proteins and 52−58% carbohydrate (75% in the form of complex carbohydrate) while the cholesterol intake was less than 210 mg day$^{-1}$. Daily fibre assumption was greater than 58 mg. The study protocol was approved by the ethics review board and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each patient.

Study protocol for isolation and count of EPCs

Mononuclear cells were isolated by density gradient centrifugation with Biocoll (Biochrom, Berlin, Germany) from 20 mL of venous blood as previously described in detail (4, 28). Briefly, after isolation, 4×10$^6$ mononuclear cells were placed on 24-well culture dishes blankets with human fibronectin (Sigma-Aldrich, Munich, Germany) and kept in endothelial basal medium (Cambrex, Walkerville, MD, USA) enriched with endothelial growth medium and 20% fetal calf serum. After the 4th day in culture, non-engrafted cells were detached by thorough washing with phosphate-buffered saline (PBS).

Characterization of late EPCs

Was assessed the uptake of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled acetylated low-density lipoprotein (DiLDL) by cells as described in detail (4, 28). Incubation of cells with DiLDL (2.4 μg/mL) was performed at 37°C for 1 hour. Then, cells were fixed with 2% paraformaldehyde for 10 min and incubated with fluorescein-5-isothiocyanate (FITC)-labeled agglutinin I (lectin, 10 μg/mL, Sigma-Aldrich, Milan, Italy) for 1 hour. Dual-staining cells positive for both lectin and DiLDL were considered as EPCs. The endothelial features were additionally documented by flow cytometry analysis of vascular endothelial growth factor receptor 2 (KDR) and von Willebrand factor (4, 28). The number of EPCs was evaluated by count-
ing carefully selected high-power fields (4, 28).

**Measurement of functional capacity of EPCs**

Isolated EPCs were separated using 1 mmol/L ethylenediaminetetraacetic acid in PBS (pH 7.4), harvested by centrifugation, resuspended in 500 μL endothelial basal medium, counted, and placed in the upper chamber of a modified Boyden chamber (2×10^6 cells; BD Bioscience, Milan, Italy) as described in our previous studies (4, 28). For identification, cell nuclei were marked with 4',6'-diamidino-2-phenylindole. Cells migrating into the lower chamber were quantified in several random microscopic fields (4, 28).

**Bone marrow mononuclear cells**

Bone marrow-derived mononuclear cells (BM-MNCs) were isolated from bone marrow aspirates by density gradient centrifugation. After two washing procedures, we performed a cell suspension using an X-vivo medium (Cambrex, Walkerville, MD, USA) with heterogeneous cell populations including hematopoietic progenitor cells (4, 28).

**Flow cytometry analysis of BM-MNCs**

For the identification of hematopoietic stem/progenitor cell populations cells were added with conjugated antibodies against human CD45 (mouse FITC-labeled; BD Pharmingen, Milan, Italy), human CD34 (FITC-labeled and allophycocyanin-labeled; BD Pharmingen) and human CD133 (allophycocyanin-labeled; Miltenyi Biotec, Bologna, Italy) (4, 28).

** Colony-forming unit assay**

The BM-MNCs (1×10⁵ per well) were founded in methylcellulose plates (Methocult GF H4535, Stem Cell Technologies, Milan, Italy) enriched with stem cell factor, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, IL-3, and IL-6. Plates were analyzed under phase-contrast microscopy, and granulocyte-macrophage colony-forming units (CFU-GM, colonies >50 cells) were counted at the 14th day of incubation (4, 28).

**Measurement of high-sensitivity C-reactive protein levels**

High-sensitivity C-reactive protein from serum of type 2 DM patients and healthy controls was measured by means of particle-enhanced immunonephelometry (Dade Behring, Marburg, Germany) as previously described (4).

**Statistical analyses**

The non-parametric Mann-Whitney U test was used to assess differences between two groups. Categorical variables were compared by the chi-square test or the Fisher exact test. Bivariate correlation was calculated by Pearson correlation. A linear regression model was used to evaluate independent predictors. If not stated otherwise, data are expressed as mean±SD. Statistical significance was assumed at p≤0.05. All statistical analyses were performed using SPSS for Windows version 12.0 (SPSS Inc., Chicago, IL, USA).

**Results**

The characteristics of the study population are described in Table 1. The two populations (healthy controls and Type 2 DM patients at baseline) were comparable for age, gender, for smoking activity and for NYHA functional class. Significantly differences were assessed for number of hypertensive subjects, family history for CHD, for LDL cholesterol, and for use of drugs as statins, ACE-I/ARB, beta-blockers and diuretics in the DM group. Finally, High-sensitivity C-reactive protein was higher in Type 2 patients.

### Table 1. Baseline characteristics of the study population

|                      | Healthy controls | Type 2 diabetic patients | p-value1 |
|----------------------|------------------|--------------------------|----------|
| n                    | 17               | 45                       |          |
| Age (years)          | 54.85±4.5        | 58.2±5.4                 | NS       |
| Gender (male/female) | 12/5             | 33/12                    | NS       |
| LVEF (%)             | ND               | 46.9±6.4                 | ND       |
| NYHA functional class| 0                | 0                        |          |
| Hypertension (number)| 2                | 10                       | 0.01     |
| Smoking (number)     | 10               | 6                        | NS       |
| Family history for CHD (number) | 5 | 11 | 0.05 |
| LDL cholesterol      | 112.5±13         | 136±26                   | 0.01     |
| Statin (number)      | 0                | 22                       |          |
| ACE-I/ARB (number)   | 2                | 18                       | 0.01     |
| Beta-blockers (number)| 2             | 7                        | 0.05     |
| Diuretics (number)   | 0                | 11                       | 0.01     |
| HsCRP (mg/dL)        | 0.05±0.08        | 0.13±0.04                | 0.05     |
| Baseline HbA1c       | 3.1±0.06         | 8.7±0.5                  | 0.01     |
| After glycemic control HbA1c | 6.2±0.3         |                  |          |

Data are presented as mean±SD. ACE-I/ARB: angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; hsCRP: high-sensitivity C-reactive protein; CHD: coronary heart disease; LVEF: left ventricular ejection fraction; LDL: low density lipoproteins; NYHA: New York Heart Association; ND: not determined; NS: non-significant.

1Comparison-wise p value for comparison of healthy controls and type 2 diabetic patients.
DM patients at baseline compared to healthy control group.

As shown in Table 2, in Type 2 DM baseline, the main determinants of EPC cell number on univariate analysis were advanced age, elevated serum levels of hs-CRP and the status of diabetes. When we considered the multivariate analysis, only the presence of Type 2 DM was an independent predictor of reduced numbers of circulating EPCs, whereas all other parameters lost predictive power (Table 2). Thus, in our experimental conditions, Type 2 DM itself was an independent determinant of circulating EPC levels. The numbers of hematopoietic progenitor cells, by which the circulating EPCs presumably rise, were determined by the expression of the marker protein CD34 by flow cytometry analysis. EPC levels (CD34+/KDR+) were lower in Type 2 DM patients in comparison to healthy controls (64±13 vs 104±21, p<0.01). Relevantly, the number of EPCs in patients with Type 2 DM increased after three months of glycemic control (64±13 baseline vs 78±11 post glycemic control, p<0.04) (Fig. 1). However, the difference in EPC level (CD34+/KDR+) (FACS analysis) between the healthy controls and Type 2 DM patients, also after the glycemic control, remained statistically significant (p<0.05) (Fig. 1).

### Functional capacity of circulating EPCs at baseline and after glycemic control

The functional capacity of circulating EPCs was assessed by measuring their migratory attitude in response to VEGF. EPCs derived from patients with Type 2 DM showed a significant impaired migratory capacity assessed by EPC chemotaxis assay toward VEGF-A compared with EPCs derived from healthy controls (Fig. 1, p<0.01 vs controls). After glycemic control, migratory capacity significantly improved compared to pre-glycemic control (p<0.05) but was still significantly lower than in healthy controls. In Type 2 DM patients, on univariate analysis, the main determinants of EPC functional capacity at baseline were advanced age, elevated serum levels of hs-CRP, the family history for CHD and the status of diabetes (Table 3). After glycemic control, the only determinant was the elevated levels of hs-CRP. However, on multivariate analysis, only the presence of Type 2 DM was an independent predictor of reduced migratory capacity of EPCs (Table 3). Taken together, Type 2 DM is associated with a reduced number of circulating and functional impairment of EPCs.

![Fig. 1. Number of EPCs positive to FACS and EPCs positive to chemotaxis assay for VEGF-A in healthy group vs type 2 DM patients pre- and after glycemic control.](image)

### Table 2. Linear regression analysis: depending variable of endothelial progenitor cell number

|                      | Total population (n=62) | Type 2 diabetic patients baseline | Type 2 diabetic patients after glycemic control |
|----------------------|------------------------|----------------------------------|-----------------------------------------------|
|                      | p-value | r | p-value | p-value | r | p-value |
| Age                  | 0.006   | -0.377 | 0.074 | <0.05 | -0.263 | 0.228 |
| HsCRP                | <0.05   | -0.358 | 0.112 | <0.05 | -0.463 | 0.058 |
| Family history for CHD (number) | 0.134   | -0.114 | 0.436 | <0.05 | -0.543 | 0.042 |
| Hypertension         | 0.782   | -0.093 | 0.512 | <0.05 | -0.303 | 0.479 |
| Diabetes             | <0.05   | -0.543 | 0.042 | <0.05 | -0.303 | 0.479 |
| Smoking              | 0.086   | -0.303 | 0.479 | <0.05 | -0.463 | 0.058 |

hsCRP: high-sensitivity C-reactive protein.
significantly reduced number of CFU-GM compared to BM-MNCs from healthy controls (51±19 vs 84±32 number of colonies per $10^5$ cells, $p<0.02$ vs controls). The number of EPC CFUs also increased significantly after glycemic control (65±14 number of colonies per $10^5$ cells, $p<0.05$ vs baseline). In Type 2 DM patients at baseline, on univariate analysis, the main determinants of CFU-GM were advanced age, sum risk factors, number of CD34$^+$CD45$^+$ and CD34$^+$CD133$^+$ cells (Table 4). However, on multivariate analysis, only the presence of Type 2 DM was an independent predictor of reduced numbers of CFU-GM at baseline and after glycemic control.

### Discussion

This study confirms that EPC number and bioactivity are reduced in patients with Type 2 DM and, most importantly, shows that an intensive glycemic control in the same group of patients can restore EPC number with less pronounced but still significant improvement in their function. There is a wide evidence on the key role of circulating EPCs in the maintenance of endothelial integrity, function and angiogenesis (29, 30), with growing interest on their use as a novel therapy for cardiovascular diseases (2, 7, 31). DM is associated to decreased EPC level and function leading to a rapid development of atherosclerosis, microangiopathies and cardiovascular accidents (13-19, 25, 26, 32, 33). EPCs can be considered biological markers in the DM patients and prognostic indicators of future cardiovascular complications in these subjects (33-37). Exhaustion of the pool of progenitor cells in the bone marrow, the impaired functional capacity within the bone marrow, the reduced mobilization, survival and/or differentiation of EPCs could account for the lower circulating EPC number in DM patients (2, 7, 37). Previous studies, showed that DM patients with good glycemic control have

### Table 3. Linear regression analysis: depending variable of endothelial progenitor cell function (migratory capacity)

| Total population (n=62) | Type 2 diabetic patients baseline | Type 2 diabetic patients after glycemic control |
|-------------------------|----------------------------------|-----------------------------------------------|
|                         | p-value | $r$ | p-value | p-value | $r$ | p-value |
| Age                     | 0.004   | -0.393 | 0.040 | 0.092 | -0.319 | 0.048 |
| HsCRP                   | 0.031   | -0.384 | 0.526 | ND     | ND     | ND     |
| Family history          | 0.028   | -0.402 | 0.035 | 0.156 | 0.307 | ND     |
| Hypertension            | 0.768   | -0.012 | ND     | 0.092 | 0.304 | ND     |
| Diabetes                | 0.108   | -0.268 | 0.054 | ND     | ND     | ND     |
| Smoking                 | 0.682   | 0.058  | ND     | ND     | ND     | ND     |

hsCRP: high-sensitivity C-reactive protein.

### Table 4. Linear regression analysis: depending variable of colony-forming unit-granulocyte-macrophage

| Total population (n=62) | Type 2 diabetic patients baseline | Type 2 diabetic patients after glycemic control |
|-------------------------|----------------------------------|-----------------------------------------------|
|                         | p-value | $r$ | p-value | p-value | $r$ | p-value |
| Age                     | 0.006   | 0.293 | ND     | 0.156 | -0.286 | 0.05 |
| HsCRP                   | ND     | ND | ND     | 0.156 | -0.286 | 0.05 |
| Family history          | 0.483   | -0.082 | ND     | 0.156 | -0.286 | 0.05 |
| Hypertension            | 0.563   | 0.032 | ND     | 0.156 | -0.286 | 0.05 |
| Diabetes                | 0.106   | -0.301 | 0.05  | 0.156 | -0.286 | 0.05 |
| Smoking                 | 0.364   | -0.186 | ND     | 0.156 | -0.286 | 0.05 |
| Sum risk factors        | 0.036   | -0.307 | ND     | 0.156 | -0.286 | 0.05 |
| CD34+CD45+ cells        | 0.023   | 0.286 | ND     | 0.156 | -0.286 | 0.05 |
| CD34+CD133+ cells       | 0.037   | 0.304 | ND     | 0.156 | -0.286 | 0.05 |
| Adjusted R$^2$          | 0.260   | ND | 0.189  | ND     | ND     | ND     |
| Significance (ANOVA)    | 0.01    | ND | 0.01   | ND     | ND     | ND     |

hsCRP: high-sensitivity C-reactive protein.
a higher circulating EPC number and a better function compared to DM patients with inadequate glycemic control (18, 19, 32). Our data demonstrated that a relatively short period of intensive glycemic control in Type 2 DM patients can reverse the tendency to decline of EPC level and positively affect EPC function. We showed a close relationship among glycemic control, number and migratory response of EPCs in these patients. We adopted a standardized protocol, which showed a high capacity to detect specifically EPC subpopulations (late EPCs) (4, 28). However, we advocate that further standardization of laboratory techniques for the detection of EPCs as FACS protocols could better compare different data concerning several studies. Here, we confirm and extend previous observation that DM patients show a functional impairment of EPCs both in the BM as well as in peripheral blood as circulating progenitors. A relevant data was that, after adjusting for other cardiovascular risk factors and medications, the glycemic control was identified as an independent variable for EPC count and function. On the other hand, the circulating EPC number and bioactivity in DM patients after glycemic control did not reach the EPC level of healthy controls as observed by previous studies (32). Interestingly, in type 2 DM patients, the glycemic control has a greater impact on the number of circulating EPC with respect to the increase of CFU. This data suggests that EPC migratory response is less restored in comparison to EPCs levels. We believe that these results need to be confirmed in larger cohorts of diabetic subjects considering also extended periods of glycemic restriction. Our results indicate that in Type 2 DM patients, glucose control may be considered a mechanism to preserve EPC pool inverting the diabetic degenerative pattern coupled with endothelial dysfunction, progression of atherosclerosis and cardio circulatory complications.

This study is only an observational research. Additional investigation is needed to explore the mechanism of the increase of EPCs after glucose control. Furthermore, taking into consideration the different treatment categories used by enrolled patients, we suggest randomized-controlled clinical trials focusing on the effect of single anti-diabetic drugs on EPC pool (16, 38, 39). Further researches are needed to validate our findings in patients subjected to different pharmacological treatments in addition to the dietary regimen.

Acknowledgments

Supported partially by PRIN-MIUR 2006-2008 and Foundation Jerome Lejeune grants (Prof. Napoli).

Potential conflict of interest

The authors have no conflicting financial interest.

References

1. Sommese L, Vasco M, Costa D, Napoli C. Endothelial progenitor cells and human diseases. Ann Hematol 2014;93: 533-534
2. Napoli C, Hayashi T, Cacciatore F, Casamassimi A, Casini C, Al-Omran M, Ignarro LJ. Endothelial progenitor cells as therapeutic agents in the microcirculation: an update. Atherosclerosis 2011;215:9-22
3. Wojakowski W, Kucia M, Kazmerski M, Ratajczak MZ, Tendera M. Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: relevant reparatory mechanism? Heart 2008;94:27-33
4. Liguori A, Fiorito C, Balestrieri ML, Crimi E, Bruzzese G, Williams-Ignarro S, D’Amora M, Sommese L, Grimaldi V, Minucci PB, Giovan A, Farzati B, Ignarro LJ, Napoli C. Functional impairment of hematopoietic progenitor cells in patients with coronary heart disease. Eur J Haematol 2008; 80:258-264
5. Valgimigli M, Rigolin GM, Fucili A, Porta MD, Soukho movskaja O, Malagutti P, Bugli AM, Dragotti LZ, Francolini G, Mauro E, Castoldi G, Ferrari R, CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 2004;110:1209-1212
6. King TF, McDermott JH. Endothelial progenitor cells and cardiovascular disease. J Stem Cells 2014;9:93-106
7. Grimaldi V, Mancini FP, Casamassimi A, Al-Omran M, Zullo A, Infante T, Napoli C. Potential benefits of cell therapy in coronary heart disease. J Cardiol 2013;62:267-276
8. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmel S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005;39:733-742
9. Cheng Z, Jiang X, Pansuria M, Fang P, Mai J, Mallilank karaman K, Gandhirajan RK, Eguchi S, Scalia R, Madesh M, Yang X, Wang H. Hyperhomocysteinemia and hyperglycemia induce and potentiate endothelial dysfunction via μ-calpain activation. Diabetes 2015;64:947-959
10. Tousoulis D, Papageorgiou N, Androulakis E, Siassos G, Latsios G, Tentolouris K, Stefanadis C. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol 2013; 62:667-676
11. de Nigris F, Rienzo M, Sessa M, Infante T, Cesario E, Ignarro LJ, Al-Omran M, Giordano A, Palinski W, Napoli C. Glycoxydation promotes vascular damage via MAPK-ERK/JNK pathways. J Cell Physiol 2012;227:3639-3647
12. Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res 2001;49:554-560
13. Yiu KH, Tse HF. Specific role of impaired glucose metabolism and diabetes mellitus in endothelial progenitor cell
characteristics and function. Arterioscler Thromb Vasc Biol 2014;34:1136-1143

14. Nowak WN, Borys S, Kusińska K, Bukowska-Straková K, Witek P, Koblik T, Józkwicz A, Małecki MT, Dulak J. Number of circulating pro-angiogenic cells, growth factor and anti-oxidative gene profiles may be altered in type 2 diabetes with and without diabetic foot syndrome. J Diabetes Investig 2014;5:99-107

15. Westerweel PE, Teraa M, Rafii S, Jaspers JE, White IA, Hooper AT, Doevendans PA, Verhaar MC. Impaired endothelial progenitor cell mobilization and dysfunctional bone marrow stroma in diabetes mellitus. PLoS One 2013;8:e60357

16. Desouza CV. Does drug therapy reverse endothelial progenitor cell dysfunction in diabetes? J Diabetes Complications 2013;27:519-525

17. Jiraritthamrong C, Kheolamai P, U-Pratya Y, Chaysomrit M, Supokawej A, Manochantr S, Tantrawatpan C, Sritanau-domchai H, Issaragrisil S. In vitro vessel-forming capacity of endothelial progenitor cells in high glucose conditions. Ann Hematol 2012;91:311-320

18. Yue WS, Lau KK, Siu CW, Wang M, Yan GH, Yiu KH, Tse HF. Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2011;10:113

19. António N, Fernandes R, Soares A, Soares F, Lopes A, Carvalheiro T, Paiva A, Pêgo GM, Providência LA, Gonçalves L, Ribeiro CF. Reduced levels of circulating endothelial progenitor cells in acute myocardial infarction patients with diabetes or pre-diabetes: accompanying the glycemic continuum. Cardiovasc Diabetol 2014;13:101

20. Pikkemaat M, Melander O, Mølstad S, Garberg G, Bostrom KB, C-peptide concentration, mortality and vascular complications in people with Type 2 diabetes. The Skaraborg Diabetes Register. Diabet Med 2015;32:85-89

21. Kunz GA, Liang G, Cuculí F, Gregg D, Vata KC, Shaw LK, Goldschmidt-Clermont PJ, Dong C, Taylor DA, Petersen ED. Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J 2006;152:190-195

22. Fadini GP. A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications. Diabetologia 2014;57:4-15

23. Westerweel PE, Teraa M, Rafii S, Jaspers JE, White IA, Hooper AT, Doevendans PA, Verhaar MC. Impaired endothelial progenitor cell mobilization and dysfunctional bone marrow stroma in diabetes mellitus. PLoS One 2013;8:e60357

24. Saito H, Yamamoto Y, Yamamoto H. Diabetes alters subsets of endothelial progenitor cells that reside in blood, bone marrow, and spleen. Am J Physiol Cell Physiol 2012; 302:C892-901

25. Zhang J, Zhang X, Li H, Cui X, Guan X, Tang K, Jin C, Cheng M. Hyperglycaemia exerts deleterious effects on late endothelial progenitor cell secretion actions. Diab Vasc Dis Res 2013;10:49-56

26. Cubbon RM, Kahn MB, Wheatcroft SB. Effects of insulin resistance on endothelial progenitor cells and vascular repair. Clin Sci (Lond) 2009;117:173-190

27. Liguori A, Abete P, Hayden JM, Cacciarelli F, Rengo F, Ambrosio G, Bonaduce D, Condorelli M, Reaven PD, Napoli C. Effect of glycemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J 2001;22:2075-2084

28. Casamassimi A, Balestrieri ML, Fiorito C, Schiano C, Maione C, Rosselli R, Grimaldi V, Del Giudice V, Balestrieri C, Farzati B, Sica V, Napoli C. Comparison between total endothelial progenitor cell isolation versus enriched CD133+ culture. J Biochem 2007;141:503-511

29. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schattenman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-967

30. Urbich C, Aicher A, Hessechen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmeler S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005;39:733-742

31. Losordo DW, Kibble MR, Mendelsohn F, Marston W, Driver V, Sharafuddin M, Teo-Dorescu V, Wiechmann BN, Thompson C, Kraiss L, Carman T, Dohad S, Huang P, Junge CE, Story K, Weistroffer T, Torre M, Millay M, Runyon JP, Schainfeld R; Autologous CD34+ Cell Therapy for Critical Limb Ischemia Investigators. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv 2012; 5:821-830

32. Churchillman W, Kheolamai P, Manochantr S, Tapanadechipone P, Tantrawatpan C, U-Pratya Y, Issaragrisil S. Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control. BMC Endocr Disord 2010;10:5

33. Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, Dimmeler S, Zeiher AM. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005;111:2981-2987

34. Sambataro M, Seganfreddo E, Del Pup J, Junge CE, Story K, Weistroffer T, Thorne TM, Millay M, Runyon JP, Schainfeld R; Autologous CD34+ Cell Therapy for Critical Limb Ischemia Investigators. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv 2012; 5:821-830

35. Ambrosi G, Bonaduce D, Condorelli M, Reaven PD, Napoli C. Effect of glycemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J 2001;22:2075-2084
early phase of acute myocardial infarction. Blood 2005; 105:199-206
37. Kotlinowski J, Dulak J, Józkowicz A. Type 2 diabetes mellitus impairs endothelial progenitor cells functions. Postepy Biochem 2013;59:257-266
38. Pistrosch F, Herbrig K, Oelschlägel U, Richter S, Passauer J, Fischer S, Gross P. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 2005;183:163-167
39. Raptis AE, Markakis KP, Mazioti MC, Ikonomidis I, Maratou EP, Vlahakos DV, Kotsifaki EE, Voumouvakis AN, Tsirogianni AG, Lambadiari VA, Lekakis JP, Raptis SA, Dimitriadis GD. Effect of aliskiren on circulating endothelial progenitor cells and vascular function in patients with type 2 diabetes and essential hypertension. Am J Hypertens 2015;28:22-29